MarketLens

Is Vaxcyte's VAX-31 a Game-Changer in the Vaccine Landscape

5 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

How is the Stablecoin Landscape Shifting in 2026

5 months ago

What Defines the Fintech Landscape in 2026

6 months ago

Vaxcyte's Insider Exodus: Why CEO Sales Cloud a Bullish Biotech Narrative

2 weeks ago

Did Moderna's Q4 Earnings Beat Outweigh the Flu Vaccine Setback

6 months ago

CancerVax Develops Novel Smart mRNA to Harness Pre-Existing Immunity in 99% of World Population

CancerVax developed a single Polyepitope Smart mRNA that disguises cancer cells as viral infections, potentially harnessing pre-existing immunity in 99% of the world population.

Stock News•3 months ago

Biotech's Next Wave May Already be in Motion

The biotech and pharma sector is entering a pivotal growth phase driven by increased insider conviction, late-stage clinical successes, and emerging platform technologies. These factors are currently ...

NTHI

Stock News•3 months ago

Vaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV Market

Vaxcyte is transitioning into a commercial-stage vaccine platform, supported by over $2.4B in cash and a completed manufacturing facility. The company is currently advancing VAX-31, a 31-valent pneumo...

PCVX

Stock News•3 months ago

CARB-X awards funding to AdJane to advance its nOMV platform-derived vaccine for the prevention of gonorrhea

AdJane was awarded US$2.6 million by CARB-X to accelerate the development of its nOMV platform-derived vaccine. This funding aims to advance the candidate for the prevention of gonorrhea, a growing co...